BFRI News and Press, Biofrontera Inc. From 12/01/21

WOBURN, MA., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc . (Nasdaq: BFRI; BFRIW) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the closing of a private placement with a single instit...

Gainers: Arbutus Biopharma (NASDAQ:ABUS) +87%. MDJM (NASDAQ:MDJH) +41%. Context Therapeutics (NASDAQ:CNTX) +35%. Build-A-Bear Workshop (NYSE:BBW) +33%. Ardelyx (NASDAQ:ARDX) +28%. Ambarella (NASDAQ:AMBA) +25%. Roivant Sciences (NASDAQ:ROIV) +22%. Stran & Company (NASDAQ:STRN) +20%. Marpai...

Biofrontera Inc. (BFRI) Q3 2021 Earnings Conference Call November 30, 2021 4:30 PM ET Company Participants Pamela Keck – Head-Investor Relations Hermann Lübbert – Executive Chairman and Chief Executive Officer-Biofrontera AG Erica Monaco – Chief Executive Officer Con...

Shares of Biofrontera (BFRI -13.9%) were hit this morning after the company reported Q3 2021 results that included a significant increase in net loss compared to the year-ago period. Its net loss widened ~436% to ~$16M driven by negative EBITDA in the quarter of ~$15.8M. Operating expenses qu...

Biofrontera (NASDAQ:BFRI): Q3 net loss was $16.0M and $3.0M for the three months ended September 30, 2021 and 2020, respectively. Revenue of $4.3M (+30.3% Y/Y) Press Release Cash and cash equivalents as of September 30, 2021 were $1.7M. For further details see: Biofrontera reports Q3 re...

Conference c all at 4:30 p.m. Eastern t ime today WOBURN, Mass., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today finan...

Biofrontera (NASDAQ: BFRI, BFRIW) , a biopharmaceutical company specializing in the commercialization of dermatological products, has closed its underwritten initial public offering of 3,600,000 units. According to the update, each unit consisted of (i) one share of common stock and (ii) on...

Shares of Biofrontera Inc. (NASDAQ:BFRI) traded at a new 52-week high today of $10.40. This new high was reached on above average trading volume as 20.6 million shares traded hands, while the average 30-day volume is approximately 8.4 million shares. Biofrontera Inc is a biopharmaceutica...

Biofrontera (BFRI -12.3%) entered into a securities purchase agreement with a single institutional investor for the purchase of 2.86M shares and warrants in a private placement. The combined purchase price for one share and a warrant to purchase one share is $5.25; warrants have an ...

WOBURN, MA., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Biofrontera, Inc. (Nasdaq: BFRI; BFRIW), today announced today that it has entered into a securities purchase agreement with a single institutional investor for the purchase of 2,857,143 shares of its common stock (or common stock equivalen...